This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Comparative Study of Probenecid and Sulfinpyrazone

EDWARD E. VELAYOS, MD; CHARLEY J. SMYTH, MD

Arch Intern Med. 1965;116(2):212-219.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

HIPPOCRATES in the fourth century BC stated that once a gouty subject developed tophi in the joints he was beyond the power of medicine.¹ This dictum of the Father of Medicine held true until the most recent times. The development of effective uricosuric agents marked the beginning of a new era in the treatment of the tophaceous stage of this ancient illness, and since then there has been rapid and steady progress in the control of this disease. By the reduction of the urate stores and the maintenance of the serum urate concentration at or near normal, it has been clearly demonstrated that acute attacks of gouty arthritis decrease or cease, tophi decrease or disappear, joint function may be improved.^2-7,23 These events have stimulated a search for the most effective urate diuretic agent capable of long-term use. The purpose of this report is to present further evidence . . . [Full Text PDF of this Article]

Author Affiliations
DENVER

From the Department of Medicine, University of Colorado School of Medicine and the Veterans Administration Hospital. Geigy Arthritis Research Fellow and presently at Johns Hopkins Hospital, Baltimore (Dr. Velayos), and Associate Professor of Medicine, University of Colorado School of Medicine (Dr. Smyth).

Footnotes
Received for publication Jan 22, 1965; accepted Feb 16.

Reprint requests to 4200 E 9th Ave, Denver, Colo 80220 (Dr. Smyth).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?